GPR139 Antagonist Patent for Depression and Neurological Disorders
Summary
USPTO granted Takeda Pharmaceutical Company Limited Patent US12590086B2 for GPR139 antagonist compounds (3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives) used in methods of treating depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and ADHD. The patent contains 27 claims and includes tablet formulations.
What changed
USPTO granted Patent US12590086B2 to Takeda Pharmaceutical Company Limited for GPR139 antagonist compounds. The patent covers 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds for therapeutic use. The 27 claims encompass methods of treating depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder.
This patent grant establishes Takeda's intellectual property rights over the specified GPR139 antagonist compounds and their medical applications. Competitors developing similar GPR139 antagonists should conduct freedom-to-operate analyses. Potential licensees seeking access to the technology should contact Takeda Pharmaceutical. The filing date was May 20, 2021, with application number 17999514.
What to do next
- Conduct freedom-to-operate analysis if developing competing GPR139 antagonist compounds
- Review patent claims for potential licensing opportunities if developing treatments for listed conditions
- Monitor patent expiry timeline for strategic planning (patents typically expire 20 years from filing)
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression
Grant US12590086B2 Kind: B2 Mar 31, 2026
Assignee
Takeda Pharmaceutical Company Limited
Inventors
Tomoaki Hasui, Satoshi Mikami, Toru Yamashita, Shinji Nakamura, Shinji Morimoto, Toshihiro Imaeda, Kazuaki Takami, Masaki Daini, Hiroyuki Kakei, Minoru Nakamura, Fumie Yamaguchi, Chunxiang Wang, Sachie Takashima, Makoto Kamata, Yuya Oguro, Shuhei Ikeda
Abstract
The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).
CPC Classifications
C07D 413/14 C07D 401/14 C07D 405/14
Filing Date
2021-05-20
Application No.
17999514
Claims
27
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.